n.a. (DSCI)

0.00
NASDAQ
Prev Close 0.00
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.00 / 0.00
Exchange NASDAQ
Div & Yield N.A. (N.A)
Derma Sciences To Participate In The 25th Annual Piper Jaffray Healthcare Conference

Derma Sciences To Participate In The 25th Annual Piper Jaffray Healthcare Conference

Insert in first graph, first sentence, after 2:00 p.m.

Derma Sciences Reports Third Quarter Financial Results

Derma Sciences Reports Third Quarter Financial Results

Derma Sciences, Inc. (Nasdaq:DSCI), a medical device and pharmaceutical company focused on advanced wound care, today reported financial and operating results for the three and nine months ended September 30, 2013.

Derma Sciences To Participate In The Canaccord Genuity Medical Technology & Diagnostics Forum

Derma Sciences To Participate In The Canaccord Genuity Medical Technology & Diagnostics Forum

Derma Sciences, Inc. (Nasdaq:DSCI), a medical device and pharmaceutical company focused on advanced wound care, announced today that Edward J.

Derma Sciences Becomes Oversold (DSCI)

Derma Sciences Becomes Oversold (DSCI)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Derma Sciences To Hold Third Quarter Financial Results Conference Call On November 13th

Derma Sciences To Hold Third Quarter Financial Results Conference Call On November 13th

Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care, announced today that it will hold a conference call on November 13, 2013 to discuss the financial results...

Derma Sciences To Showcase MEDIHONEY® And TCC-EZ® At Novation Innovative Technology Expo

Derma Sciences To Showcase MEDIHONEY® And TCC-EZ® At Novation Innovative Technology Expo

Derma Sciences, Inc. (Nasdaq:DSCI), a medical device and pharmaceutical company focused on advanced wound care, is showcasing its MEDIHONEY® line of advanced wound care dressings and its TCC-EZ® Total ...

Derma Sciences Is Now Oversold (DSCI)

Derma Sciences Is Now Oversold (DSCI)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Derma Sciences Acquires 7.3% Of Comvita To Support Vertical Integration Of Key Component In MEDIHONEY® Products

Derma Sciences Acquires 7.3% Of Comvita To Support Vertical Integration Of Key Component In MEDIHONEY® Products

Derma Sciences, Inc. (Nasdaq:DSCI), a medical device and pharmaceutical company focused on advanced wound care, today announced a $7.

Derma Sciences Reports Second Quarter Financial Results

Derma Sciences Reports Second Quarter Financial Results

Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care, today reported financial and operating results for the three and six months ended June 30, 2013.

Derma Sciences Ships First MEDIHONEY Over-the-counter Product To Leading U.S. Pharmacy Chain

Derma Sciences Ships First MEDIHONEY Over-the-counter Product To Leading U.S. Pharmacy Chain

Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care, today reported that it has made an initial shipment of its first honey-based over-the-counter (OTC) ...

Derma Sciences To Present At The Canaccord Genuity 33rd Annual Growth Conference

Derma Sciences To Present At The Canaccord Genuity 33rd Annual Growth Conference

Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care, announced today that Edward J.

Derma Sciences To Hold Second Quarter Financial Results Conference Call On August 12th

Derma Sciences To Hold Second Quarter Financial Results Conference Call On August 12th

Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care, announced today that it will hold a conference call on August 12, 2013 to discuss the financial results...

Derma Sciences CEO Highlights Rapid Growth Of MEDIHONEY Products In Presentation At Comvita Annual Meeting

Derma Sciences CEO Highlights Rapid Growth Of MEDIHONEY Products In Presentation At Comvita Annual Meeting

Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care, announces that its chief executive officer, Edward J.

DSCI January 2014 Options Begin Trading

DSCI January 2014 Options Begin Trading

Investors in Derma Sciences Inc. saw new options begin trading today, for the January 2014 expiration.

Derma Sciences Announces Timing For Fourth Quarter Conference Call And 2012 Form 10-K Filing

Derma Sciences Announces Timing For Fourth Quarter Conference Call And 2012 Form 10-K Filing

Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care, announced today that the Company will file its Form 10-K for 2012 with the U.

Derma Sciences To Present At The 25th Annual ROTH Conference

Derma Sciences To Present At The 25th Annual ROTH Conference

Derma Sciences, Inc. (the “Company”) (Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care, announced today that the Company will be presenting at the 25 th Annual ROTH...

Derma Sciences Initiates Enrollment In DSC127 Phase 3 Trial For Healing Diabetic Foot Ulcers

Derma Sciences Initiates Enrollment In DSC127 Phase 3 Trial For Healing Diabetic Foot Ulcers

Derma Sciences, Inc. (the “Company”) (Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care, announces that enrollment of patients has commenced in the first of two Phase 3 ...

Derma Sciences Closes $36.4 Million Underwritten Public Offering Of Common Stock, Including Full Over-Allotment

Derma Sciences Closes $36.4 Million Underwritten Public Offering Of Common Stock, Including Full Over-Allotment

Derma Sciences, Inc. (the “Company”) (Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care, today announced the closing of an underwritten public offering of 3,521,300 ...

Derma Sciences Announces Pricing Of Underwritten Public Offering Of Common Stock

Derma Sciences Announces Pricing Of Underwritten Public Offering Of Common Stock

Derma Sciences, Inc. (the “Company”)(Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care, today announced the pricing of an underwritten public offering of 3,062,000 shares of...

Derma Sciences Announces Commencement Of Public Offering Of Common Stock

Derma Sciences Announces Commencement Of Public Offering Of Common Stock

Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care, today announced that it intends to offer shares of its common stock in a public offering.

Derma Sciences To Present At Two Upcoming Conferences

Derma Sciences To Present At Two Upcoming Conferences

Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care, announced today that Edward J.

Derma Sciences To Present At The 24th Annual Piper Jaffray Healthcare Conference

Derma Sciences To Present At The 24th Annual Piper Jaffray Healthcare Conference

Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care, announced today that Edward J.

Derma Sciences To Present At The Lazard Capital Markets 9th Annual Healthcare Conference

Derma Sciences To Present At The Lazard Capital Markets 9th Annual Healthcare Conference

Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care, announced today that Edward J.

Derma Sciences Reports Third Quarter 2012 Financial Results

Derma Sciences Reports Third Quarter 2012 Financial Results

Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care, today reported financial and operating results for the three and nine months ended September 30, 2012.

Derma Sciences To Hold Third Quarter Financial Results Conference Call On November 12th

Derma Sciences To Hold Third Quarter Financial Results Conference Call On November 12th

Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care, announced today that the Company will hold a conference call on November 12, 2012 to discuss the...

Derma Sciences On Track To Begin Phase 3 Program With DSC127 In December Following Meeting With FDA

Derma Sciences On Track To Begin Phase 3 Program With DSC127 In December Following Meeting With FDA

Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care, today reported that based on a meeting held last week with the U.

Pilot Study In Patients With Head And Neck Cancer Finds That Derma Sciences’ MEDIHONEY® Reduces Hospital Stays In The U.K.

Pilot Study In Patients With Head And Neck Cancer Finds That Derma Sciences’ MEDIHONEY® Reduces Hospital Stays In The U.K.

Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care, today reported an independent pilot study conducted in the U.

Derma Sciences Launches MEDIHONEY® HCS In The U.S.

Derma Sciences Launches MEDIHONEY® HCS In The U.S.

Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care, today announced the U.

Derma Sciences To Present At The Rodman And Renshaw Annual Global Investment Conference

Derma Sciences To Present At The Rodman And Renshaw Annual Global Investment Conference

Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care announced today that Edward J.

Derma Sciences Reports Second Quarter 2012 Financial Results

Derma Sciences Reports Second Quarter 2012 Financial Results

Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care, today reported financial and operating results for the three and six months ended June 30, 2012.